CD47和CD68在乳腺癌中的表达与肿瘤浸润淋巴细胞、血管浸润、检测方式和预后相关

IF 3.4 2区 医学 Q1 PATHOLOGY
Ying Chen, Tor Audun Klingen, Hans Aas, Elisabeth Wik, Lars A Akslen
{"title":"CD47和CD68在乳腺癌中的表达与肿瘤浸润淋巴细胞、血管浸润、检测方式和预后相关","authors":"Ying Chen,&nbsp;Tor Audun Klingen,&nbsp;Hans Aas,&nbsp;Elisabeth Wik,&nbsp;Lars A Akslen","doi":"10.1002/cjp2.309","DOIUrl":null,"url":null,"abstract":"<p>CD47 expressed on tumor cells binds to signal regulatory protein alpha on macrophages, initiating inhibition of phagocytosis. We investigated the relationships between tumor expression of CD47 and CD68 macrophage content, subsets of tumor-infiltrating lymphocytes (TILs), and vascular invasion in breast cancer. A population-based series of 282 cases (200 screen detected and 82 interval patients) from the Norwegian Breast Cancer Screening Program was examined. Immunohistochemical staining for CD47 and CD68 was evaluated on tissue microarray (TMA) slides. For CD47 evaluation, a staining index was used. CD68 tumor-associated macrophages were counted and dichotomized. TIL subsets (CD45, CD3, CD4, CD8, and FOXP3) were counted and dichotomized using immunohistochemistry on TMA slides. Vascular invasion (both lymphatic and blood vessel) was determined on whole tissue slides. High CD47 tumor cell expression or high counts of CD68 macrophages were significantly associated with elevated levels of all TIL subsets (<i>p</i> &lt; 0.02), CD163 macrophages (<i>p</i> &lt; 0.001), blood vessel invasion (CD31 positive) (<i>p</i> &lt; 0.01), and high tumor cell Ki67 (<i>p</i> &lt; 0.004). High CD47 expression was associated with ER negativity (<i>p</i> &lt; 0.001), HER2 positive status (<i>p</i> = 0.03), and interval-detected tumors (<i>p</i> = 0.03). Combined high expression of CD47–CD68 was associated with a shorter recurrence-free survival (RFS) by multivariate analysis (hazard ratio [HR]: 2.37, <i>p</i> = 0.018), adjusting for tumor diameter, histologic grade, lymph node status, and molecular subtype. Patients with luminal A tumors showed a shorter RFS for CD47–CD68 high cases by multivariate assessment (HR: 5.73, <i>p</i> = 0.004). This study demonstrates an association of concurrent high CD47 tumor cell expression and high CD68 macrophage counts with various TIL subsets, blood vessel invasion (CD31 positive), other aggressive tumor features, and interval-presenting breast cancer. Our findings suggest a link between CD47, tumor immune response, and blood vessel invasion (CD31 positive). Combined high expression of CD47–CD68 was an independent prognostic factor associated with poor prognosis in all cases, as well as in the luminal A category.</p>","PeriodicalId":48612,"journal":{"name":"Journal of Pathology Clinical Research","volume":"9 3","pages":"151-164"},"PeriodicalIF":3.4000,"publicationDate":"2023-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://pathsocjournals.onlinelibrary.wiley.com/doi/epdf/10.1002/cjp2.309","citationCount":"0","resultStr":"{\"title\":\"CD47 and CD68 expression in breast cancer is associated with tumor-infiltrating lymphocytes, blood vessel invasion, detection mode, and prognosis\",\"authors\":\"Ying Chen,&nbsp;Tor Audun Klingen,&nbsp;Hans Aas,&nbsp;Elisabeth Wik,&nbsp;Lars A Akslen\",\"doi\":\"10.1002/cjp2.309\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>CD47 expressed on tumor cells binds to signal regulatory protein alpha on macrophages, initiating inhibition of phagocytosis. We investigated the relationships between tumor expression of CD47 and CD68 macrophage content, subsets of tumor-infiltrating lymphocytes (TILs), and vascular invasion in breast cancer. A population-based series of 282 cases (200 screen detected and 82 interval patients) from the Norwegian Breast Cancer Screening Program was examined. Immunohistochemical staining for CD47 and CD68 was evaluated on tissue microarray (TMA) slides. For CD47 evaluation, a staining index was used. CD68 tumor-associated macrophages were counted and dichotomized. TIL subsets (CD45, CD3, CD4, CD8, and FOXP3) were counted and dichotomized using immunohistochemistry on TMA slides. Vascular invasion (both lymphatic and blood vessel) was determined on whole tissue slides. High CD47 tumor cell expression or high counts of CD68 macrophages were significantly associated with elevated levels of all TIL subsets (<i>p</i> &lt; 0.02), CD163 macrophages (<i>p</i> &lt; 0.001), blood vessel invasion (CD31 positive) (<i>p</i> &lt; 0.01), and high tumor cell Ki67 (<i>p</i> &lt; 0.004). High CD47 expression was associated with ER negativity (<i>p</i> &lt; 0.001), HER2 positive status (<i>p</i> = 0.03), and interval-detected tumors (<i>p</i> = 0.03). Combined high expression of CD47–CD68 was associated with a shorter recurrence-free survival (RFS) by multivariate analysis (hazard ratio [HR]: 2.37, <i>p</i> = 0.018), adjusting for tumor diameter, histologic grade, lymph node status, and molecular subtype. Patients with luminal A tumors showed a shorter RFS for CD47–CD68 high cases by multivariate assessment (HR: 5.73, <i>p</i> = 0.004). This study demonstrates an association of concurrent high CD47 tumor cell expression and high CD68 macrophage counts with various TIL subsets, blood vessel invasion (CD31 positive), other aggressive tumor features, and interval-presenting breast cancer. Our findings suggest a link between CD47, tumor immune response, and blood vessel invasion (CD31 positive). Combined high expression of CD47–CD68 was an independent prognostic factor associated with poor prognosis in all cases, as well as in the luminal A category.</p>\",\"PeriodicalId\":48612,\"journal\":{\"name\":\"Journal of Pathology Clinical Research\",\"volume\":\"9 3\",\"pages\":\"151-164\"},\"PeriodicalIF\":3.4000,\"publicationDate\":\"2023-01-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://pathsocjournals.onlinelibrary.wiley.com/doi/epdf/10.1002/cjp2.309\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Pathology Clinical Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/cjp2.309\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PATHOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pathology Clinical Research","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cjp2.309","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PATHOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

肿瘤细胞上表达的CD47与巨噬细胞上的信号调节蛋白α结合,启动吞噬抑制。我们研究了乳腺癌中CD47和CD68巨噬细胞含量、肿瘤浸润淋巴细胞亚群(TILs)的表达和血管浸润之间的关系。对来自挪威乳腺癌筛查项目的282例(200例筛查到的病例和82例间隔期患者)进行了基于人群的系列研究。在组织微阵列(TMA)载玻片上评估CD47和CD68的免疫组化染色。CD47的评价采用染色指标。对CD68肿瘤相关巨噬细胞进行计数和二分类。利用免疫组化技术对TMA载玻片上的TIL亚群(CD45、CD3、CD4、CD8和FOXP3)进行计数和二分类。血管浸润(淋巴和血管)在整个组织切片上被确定。高CD47肿瘤细胞表达或高CD68巨噬细胞计数与TIL所有亚群(p < 0.02)、CD163巨噬细胞(p < 0.001)、血管侵袭(CD31阳性)(p < 0.01)和高肿瘤细胞Ki67 (p < 0.004)水平升高显著相关。高CD47表达与ER阴性(p < 0.001)、HER2阳性(p = 0.03)和间隔检测肿瘤(p = 0.03)相关。多因素分析显示,考虑肿瘤直径、组织学分级、淋巴结状态和分子亚型,CD47-CD68联合高表达与较短的无复发生存期(RFS)相关(风险比[HR]: 2.37, p = 0.018)。多因素评估显示,腔内A肿瘤患者CD47-CD68高的RFS较短(HR: 5.73, p = 0.004)。该研究表明,同时高CD47肿瘤细胞表达和高CD68巨噬细胞计数与各种TIL亚群、血管侵袭(CD31阳性)、其他侵袭性肿瘤特征和间期表现乳腺癌存在关联。我们的研究结果表明,CD47、肿瘤免疫反应和血管侵袭(CD31阳性)之间存在联系。CD47-CD68联合高表达是与所有病例及腔内A类患者预后不良相关的独立预后因素。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

CD47 and CD68 expression in breast cancer is associated with tumor-infiltrating lymphocytes, blood vessel invasion, detection mode, and prognosis

CD47 and CD68 expression in breast cancer is associated with tumor-infiltrating lymphocytes, blood vessel invasion, detection mode, and prognosis

CD47 expressed on tumor cells binds to signal regulatory protein alpha on macrophages, initiating inhibition of phagocytosis. We investigated the relationships between tumor expression of CD47 and CD68 macrophage content, subsets of tumor-infiltrating lymphocytes (TILs), and vascular invasion in breast cancer. A population-based series of 282 cases (200 screen detected and 82 interval patients) from the Norwegian Breast Cancer Screening Program was examined. Immunohistochemical staining for CD47 and CD68 was evaluated on tissue microarray (TMA) slides. For CD47 evaluation, a staining index was used. CD68 tumor-associated macrophages were counted and dichotomized. TIL subsets (CD45, CD3, CD4, CD8, and FOXP3) were counted and dichotomized using immunohistochemistry on TMA slides. Vascular invasion (both lymphatic and blood vessel) was determined on whole tissue slides. High CD47 tumor cell expression or high counts of CD68 macrophages were significantly associated with elevated levels of all TIL subsets (p < 0.02), CD163 macrophages (p < 0.001), blood vessel invasion (CD31 positive) (p < 0.01), and high tumor cell Ki67 (p < 0.004). High CD47 expression was associated with ER negativity (p < 0.001), HER2 positive status (p = 0.03), and interval-detected tumors (p = 0.03). Combined high expression of CD47–CD68 was associated with a shorter recurrence-free survival (RFS) by multivariate analysis (hazard ratio [HR]: 2.37, p = 0.018), adjusting for tumor diameter, histologic grade, lymph node status, and molecular subtype. Patients with luminal A tumors showed a shorter RFS for CD47–CD68 high cases by multivariate assessment (HR: 5.73, p = 0.004). This study demonstrates an association of concurrent high CD47 tumor cell expression and high CD68 macrophage counts with various TIL subsets, blood vessel invasion (CD31 positive), other aggressive tumor features, and interval-presenting breast cancer. Our findings suggest a link between CD47, tumor immune response, and blood vessel invasion (CD31 positive). Combined high expression of CD47–CD68 was an independent prognostic factor associated with poor prognosis in all cases, as well as in the luminal A category.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Pathology Clinical Research
Journal of Pathology Clinical Research Medicine-Pathology and Forensic Medicine
CiteScore
7.40
自引率
2.40%
发文量
47
审稿时长
20 weeks
期刊介绍: The Journal of Pathology: Clinical Research and The Journal of Pathology serve as translational bridges between basic biomedical science and clinical medicine with particular emphasis on, but not restricted to, tissue based studies. The focus of The Journal of Pathology: Clinical Research is the publication of studies that illuminate the clinical relevance of research in the broad area of the study of disease. Appropriately powered and validated studies with novel diagnostic, prognostic and predictive significance, and biomarker discover and validation, will be welcomed. Studies with a predominantly mechanistic basis will be more appropriate for the companion Journal of Pathology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信